Literature DB >> 10777149

IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects.

M Raux1, L Finkielsztejn, D Salmon-Céron, H Bouchez, J L Excler, E Dulioust, J M Grouin, D Sicard, C Blondeau.   

Abstract

We measured total IgG1, IgG2, IgG3, and IgG4 concentrations by ELISA in serum (S), total saliva (TS), cervicovaginal secretions (CVS), seminal secretions (SPE), and rectal secretions (RS) from either CDC II/III HIV-1-infected subjects or healthy volunteers. Human serum albumin was measured in parallel to calculate the relative coefficient of excretion (RCE). Levels of IgG1 and IgG3 directed against gp120 MN also were measured by ELISA in all samples, and the specific activity (SA) calculated. HIV-1-specific IgG2 and IgG4 were not compared, as total IgG2 and total IgG4 levels in HIV-1-infected subjects were found to be lower than in the healthy controls. Despite substantial interindividual variability, total IgG1 and IgG3 concentrations in all fluids were greater in the HIV-1-infected subjects than in the healthy controls. Calculations of RCE indicated predominantly a transudative origin for IgG subclasses in the different mucosal fluids, except for CVS, in which IgG1, IgG2, and IgG4 was produced locally. The transduction behavior of IgG3 in secretions appears to be different from that of other IgG subclasses. HIV-1-infected subjects were considered positive for IgG1 and IgG3 antibodies against gp120 MN if their antibody levels exceeded the maximum titer measured in the control group. Positive levels of anti-gp120 MN IgG1 were detected for 100% of HIV-1-infected individuals in S, CVS, and SPE, 97% in TS, and 75% in RS. Fewer subjects had positive levels of IgG3 to gp120 MN in their secretions (maximum 67% in CVS). Despite the low concentrations of total IgG3, mean SA values for IgG3 to gp120 MN were greater in secretions than in serum. No significant difference in the SA values for IgG1 to gp120 MN was observed between the different fluids. Only CVS had a local production of HIV-specific IgG1 Our results highlight the importance of an HIV-specific IgG1 and IgG3 immune response in mucosal fluids from HIV-1-infected subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777149     DOI: 10.1089/088922200309007

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  20 in total

Review 1.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 2.  Interactions between HIV-1 and mucosal cells in the female reproductive tract.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-04-01       Impact factor: 3.886

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.

Authors:  Michael D Alpert; Andrew R Rahmberg; William Neidermyer; Sharon K Ng; Angela Carville; Jeremy V Camp; Robert L Wilson; Michael Piatak; Keith G Mansfield; Wenjun Li; Christopher J Miller; Jeffrey D Lifson; Pamela A Kozlowski; David T Evans
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

5.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Authors:  Alexandria E-B Rossheim; Tina D Cunningham; Pamela S Hair; Tushar Shah; Kenji M Cunnion; Stephanie B Troy
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

7.  Antibodies and Acidic Environment Do Not Enhance HIV-1 Transcytosis.

Authors:  Oscar A Gonzalez; Manish Sagar
Journal:  J Infect Dis       Date:  2016-08-04       Impact factor: 5.226

8.  Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.

Authors:  Katja Klein; Ronald S Veazey; Ranjit Warrier; Peter Hraber; Lara A Doyle-Meyers; Viviana Buffa; Hua-Xin Liao; Barton F Haynes; George M Shaw; Robin J Shattock
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 9.  Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.

Authors:  Jiri Mestecky; Qing Wei; Rashada Alexander; Milan Raska; Jan Novak; Zina Moldoveanu
Journal:  Am J Reprod Immunol       Date:  2014-02-05       Impact factor: 3.886

10.  An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.

Authors:  Winnie Sohn; Edward Lee; Martin K Kankam; Ogo Egbuna; Graeme Moffat; Jeanine Bussiere; Desmond Padhi; Eric Ng; Sandeep Kumar; J Greg Slatter
Journal:  Br J Clin Pharmacol       Date:  2015-12-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.